Document is current

Any future updates will be listed below

CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy—anti-Cas9 immune response casts its shadow over safety and efficacy

Crossref DOI link: https://doi.org/10.1038/s41434-022-00323-8

Published Online: 2022-02-22

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark